Company Active LTD

Company profile

Hairclone Limited

Hairclone Making hair loss history

Hairclone Limited is a UK company with status active founded in 2015.

CRN
09849505
Founded
2015
Age
10

Overview

Legal name
HAIRCLONE LIMITED
Region
Unknown
Registered address
70 QUAY STREET
MANCHESTER
UNITED KINGDOM
M3 3EJ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Hairclone Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Dec 2023 to 30 Nov 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
7

Company events

Reference milestones and recent Companies House filing stream events.

8 events
31 Aug
2026

Accounts due

Accounts Due

Next accounts due date

02 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

18 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Nov
2024

Accounts filed

Accounts

Last accounts made up date

25 Nov
2024

Second Filing Of Confirmation Statement With Made Up Date

Confirmation-statement

RP04CS01 | Transaction MzQ0NDU4Nzg1NGFkaXF6a2N4

Published 25 Nov 2024 12:29

25 Nov
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0NDc3NTE5M2FkaXF6a2N4

Published 25 Nov 2024 01:27

27 Nov
2023

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQwMTU2NDc2MmFkaXF6a2N4 | Paper/PDF filed

Published 27 Nov 2024 10:36

30 Oct
2015

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2020
Funded years
2020, 2023
Age at first award
4 years

Projects

2023 Collaborative R&D Lead participant

Co-development of novel cell produced treatments for hair follicle stimulation

1 Nov 2023 to 31 Oct 2026

Awarded
£244,996
Total cost £349,995

HairClone in the UK and Cell Research Corporation (CRC) in Singapore will form an international collaboration to develop treatments using human cell conditioned media to transiently stimulate hair growth in patients suffering from Androgenic Alopecia. CRC are developing clinical ATMPs based on human umbilical cord lining stem cells and have also developed...

2020 Feasibility Studies Lead participant

Continuity Grant - Personalised regenerative cell therapy for androgenic alopecia

1 Jun 2020 to 31 Mar 2021

Awarded
£66,100
Total cost £66,100

no public description

2020 Study Lead participant

Personalised regenerative cell therapy for androgenic alopecia

1 Jan 2020 to 30 Jun 2021

Awarded
£153,486
Total cost £219,266

A significant proportion of men (70%) and women (40%) around the world experience hair loss at some time in their lives. The primary cause is a disease called androgenic alopecia and this results in affected hair follicles miniaturising, producing thinner, shorter hair shafts, which gives the appearance that the hair is lost. Over 1.8 million people aroun...

Product types

Collaborative R&D Feasibility Studies Study